CD226 and neurodegenerative disease: We selected 19 genes that, based on previously described genetic associations with either immune-mediated (9 genes: ATG16L1, CARD9, CD226, CDHR3, GPR35, GPR65, IFIH1, IRF5, and TYK2), cardiometabolic (8 genes: F11, F12, GDF15, GUCY1A3, KNG1, LGALS3, PNPLA3, and SLC30A8), or neurodegenerative diseases (2 genes: LRRK2, TMEM175), were evaluated as potential novel drug targets (Table 1).